Escugen and Huahui Health Form Exclusive Partnership to Develop First‑in‑Class ADC for Solid Tumors
Shanghai‑based Escugen and Beijing‑headquartered Huahui Health have announced a global, exclusive cooperation agreement to develop...
Fineline Cube
NHSA Releases Draft Regulations to Tighten Medical Insurance Funds Oversight
On September 7, 2025, China’s National Healthcare Security Administration (NHSA) issued the Draft Implementation Rules for the...
Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies
US-based Gilead Sciences’ (NASDAQ: GILD) subsidiary Kite Pharma has officially ended its $2.3 billion collaboration with Shoreline...
Junshi Biosciences’ JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its proprietary recombinant humanized...
Hengrui’s RSS0393 PDE4 Inhibitor Approved for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its proprietary topical RSS0393...
Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its investigational drug HRS‑4729...
Innovent’s Xinbimin IGF‑1R Antibody Approved in Macau
China-based Innovent Biologics Inc. (HKG: 1801) announced that the Macau Special Administrative Region drug authority...
TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced the first patient dose in an open‑label, multi‑center...
Simcere Launches Quviviq, New Insomnia Therapy in China
Jiangsu Simcere Pharmaceutical Co., Ltd. (HKG: 2096) announced the nationwide launch of its first prescription...
Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced an exclusive licensing arrangement with...
Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that it will spin off its...
Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the China National Medical...
Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the National Medical Products Administration (NMPA)...
Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China
Boji Medical Technology Co., Ltd. (SHE: 300404) has secured approval from the National Medical Products...
Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) confirmed that China’s National Medical Products...
Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has signed an evaluation...
Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs
Argo Biopharma, a Shanghai‑based siRNA drug developer, announced a new strategic cooperation agreement with Novartis...
ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs
ChemPartner Pharmatech Co., Ltd. (SHE: 300149) announced that its wholly‑owned subsidiary, Beihai ChemPartner Venture Capital...
AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
American pharmaceutical giant AbbVie (NYSE: ABBV) disclosed that its bispecific T‑cell engager, epcoritamab, has been...
Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs
Replicate Bioscience, a pioneer in self‑replicating RNA (srRNA) therapeutics, announced a landmark multi‑year research partnership...